

# Simon Tiberi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2119281/publications.pdf>

Version: 2024-02-01

173  
papers

6,630  
citations

61984

43  
h-index

76900

74  
g-index

177  
all docs

177  
docs citations

177  
times ranked

5793  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts. <i>International Journal of Infectious Diseases</i> , 2021, 113, S7-S12.	3.3	526
2	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	13.7	452
3	Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. <i>Lancet Infectious Diseases, The</i> , 2018, 18, e183-e198.	9.1	281
4	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. <i>European Respiratory Journal</i> , 2020, 56, 2001398.	6.7	273
5	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. <i>European Respiratory Journal</i> , 2017, 49, 1700387.	6.7	233
6	Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. <i>Pulmonology</i> , 2021, 27, 151-165.	2.1	172
7	Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR/XDR-TB. <i>European Respiratory Journal</i> , 2013, 41, 1386-1392.	6.7	145
8	Prognostic value of interferon- $\gamma$ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 1077-1087.	9.1	135
9	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	4.3	133
10	Direct Whole-Genome Sequencing of Sputum Accurately Identifies Drug-Resistant Mycobacterium tuberculosis Faster than MGIT Culture Sequencing. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	131
11	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	3.3	126
12	New drugs and perspectives for new anti-tuberculosis regimens. <i>Pulmonology</i> , 2018, 24, 86-98.	2.1	114
13	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019, 54, 1901522.	6.7	113
14	Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. <i>European Respiratory Review</i> , 2019, 28, 190035.	7.1	107
15	Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2017, 50, 1701462.	6.7	103
16	On tuberculosis and COVID-19 co-infection. <i>European Respiratory Journal</i> , 2020, 56, 2002328.	6.7	93
17	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1235-1243.	6.7	92
18	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	6.7	89

#	ARTICLE	IF	CITATIONS
19	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. <i>European Respiratory Journal</i> , 2021, 58, 2101786.	6.7	86
20	First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. <i>European Respiratory Journal</i> , 2016, 48, 935-938.	6.7	84
21	Classifying new anti-tuberculosis drugs: rationale and future perspectives. <i>International Journal of Infectious Diseases</i> , 2017, 56, 181-184.	3.3	82
22	Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 797-813.	1.2	78
23	Tuberculosis elimination: where are we now?. <i>European Respiratory Review</i> , 2018, 27, 180035.	7.1	76
24	Multidrug-Resistant Tuberculosis in Europe, 2010–2011. <i>Emerging Infectious Diseases</i> , 2015, 21, 409-416.	4.3	75
25	Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2016, 17, 373.	4.1	75
26	Treatment Outcomes in Multidrug-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2016, 375, 1103-1105.	27.0	73
27	A cluster of two human cases of tick-borne encephalitis (TBE) transmitted by unpasteurised goat milk and cheese in Germany, May 2016. <i>Eurosurveillance</i> , 2018, 23, .	7.0	71
28	Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1758-1766.	6.7	69
29	Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2016, 48, 1503-1507.	6.7	66
30	Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. <i>European Respiratory Journal</i> , 2016, 47, 333-336.	6.7	64
31	<i>Mycobacterium chimaera</i> infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1164-1170.	6.0	60
32	Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. <i>European Respiratory Journal</i> , 2018, 52, 1800934.	6.7	59
33	Management of patients with multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 645-662.	1.2	55
34	Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. <i>European Respiratory Journal</i> , 2014, 43, 289-292.	6.7	54
35	Delayed-onset myocarditis following COVID-19. <i>Lancet Respiratory Medicine</i> , 2021, 9, e32-e34.	10.7	54
36	Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. <i>Journal of Thoracic Disease</i> , 2017, 9, 2093-2101.	1.4	52

#	ARTICLE	IF	CITATIONS
37	Intestinal tuberculosis: a diagnostic challenge. <i>Tropical Medicine and International Health</i> , 2017, 22, 994-999.	2.3	51
38	The cursed duet today: Tuberculosis and HIV-coinfection. <i>Presse Medicale</i> , 2017, 46, e23-e39.	1.9	50
39	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update. <i>European Respiratory Journal</i> , 2018, 51, 1702678.	6.7	50
40	Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. <i>European Respiratory Journal</i> , 2015, 46, 1205-1207.	6.7	47
41	WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. <i>Lancet</i> , The, 2016, 387, 2486-2487.	13.7	47
42	Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2017, 18, 341.	4.1	47
43	Non-tuberculous mycobacterial infections – A neglected and emerging problem. <i>International Journal of Infectious Diseases</i> , 2020, 92, S46-S50.	3.3	46
44	COVID-19 and tuberculosis – threats and opportunities. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 757-760.	1.2	45
45	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2017, 23, 1718-1721.	4.3	43
46	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019, 83, 72-76.	3.3	41
47	Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. <i>Journal of Thoracic Disease</i> , 2016, 8, 2666-2671.	1.4	39
48	Applicability of the shorter “Bangladesh regimen” in high multidrug-resistant tuberculosis settings. <i>International Journal of Infectious Diseases</i> , 2017, 56, 190-193.	3.3	38
49	Drug resistant TB – latest developments in epidemiology, diagnostics and management. <i>International Journal of Infectious Diseases</i> , 2022, 124, S20-S25.	3.3	37
50	Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians. <i>Clinical Infectious Diseases</i> , 2017, 64, 104-105.	5.8	36
51	Post tuberculosis treatment infectious complications. <i>International Journal of Infectious Diseases</i> , 2020, 92, S41-S45.	3.3	36
52	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 688-694.	2.5	35
53	Different disease, same challenges: Social determinants of tuberculosis and COVID-19. <i>Pulmonology</i> , 2021, 27, 338-344.	2.1	35
54	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1188.2-1190.	5.8	34

#	ARTICLE	IF	CITATIONS
55	QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (Tbnet) study. <i>European Respiratory Journal</i> , 2018, 52, 1800537.	6.7	34
56	Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 960-964.	1.4	34
57	ERS/WHO Tuberculosis Consilium: reporting of the initial 10 cases. <i>European Respiratory Journal</i> , 2014, 43, 286-289.	6.7	32
58	Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1755-1762.	3.0	32
59	Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2021, 113, S96-S99.	3.3	32
60	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. <i>Journal of Infection</i> , 2019, 78, 35-39.	3.3	30
61	Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. <i>Pulmonology</i> , 2021, 27, 403-412.	2.1	30
62	Clinical standards for the diagnosis, treatment and prevention of TB infection. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 190-205.	1.2	29
63	Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. <i>European Respiratory Journal</i> , 2016, 48, 1527-1529.	6.7	28
64	Tuberculosis in the time of COVID-19: quality of life and digital innovation. <i>European Respiratory Journal</i> , 2020, 56, 2001998.	6.7	28
65	Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 379-386.	5.6	27
66	Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180324.	0.7	27
67	Accelerating the development of therapeutic strategies for drug-resistant tuberculosis. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 607-608.	46.4	26
68	Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries. <i>International Journal of Infectious Diseases</i> , 2020, 92, S60-S68.	3.3	26
69	Multidrug and Extensively Drug-resistant Tuberculosis. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 1063-1085.	5.1	25
70	The need for pulmonary rehabilitation following tuberculosis treatment. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 720-722.	1.2	25
71	Beyond multidrug-resistant tuberculosis in Europe: a TBNET study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1524-1527.	1.2	23
72	Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. <i>European Respiratory Journal</i> , 2016, 47, 664-667.	6.7	23

#	ARTICLE	IF	CITATIONS
73	Necrotizing pneumonia (aetiology, clinical features and management). <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 225-232.	2.6	23
74	Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections. <i>Clinical Pharmacokinetics</i> , 2021, 60, 711-725.	3.5	23
75	Imaging features and diagnosis of tuberculosis of the breast. <i>Clinical Radiology</i> , 2017, 72, 217-222.	1.1	22
76	The critically ill patient with tuberculosis in intensive care: Clinical presentations, management and infection control. <i>Journal of Critical Care</i> , 2018, 45, 184-196.	2.2	22
77	Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 713-722.	5.6	22
78	Clinical standards for the dosing and management of TB drugs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 483-499.	1.2	22
79	Challenging MDR-TB clinical problems – The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. <i>International Journal of Infectious Diseases</i> , 2019, 80, S68-S72.	3.3	21
80	Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. <i>International Journal of Infectious Diseases</i> , 2020, 92, S10-S14.	3.3	20
81	Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1025-1037.	3.1	19
82	Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 11-21.	4.4	19
83	Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond. <i>Pulmonology</i> , 2018, 24, 132-141.	2.1	19
84	Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. <i>Pulmonology</i> , 2021, 27, 248-256.	2.1	18
85	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, S90-S103.	3.3	18
86	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. <i>Journal of Medical Virology</i> , 2008, 80, 201-208.	5.0	17
87	Treatment outcomes of MDR-TB and HIV co-infection in Europe. <i>European Respiratory Journal</i> , 2017, 49, 1602363.	6.7	17
88	Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601612.	6.7	16
89	Single-center outbreak of <i>Pneumocystis jirovecii</i> pneumonia in heart transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12880.	1.7	16
90	Evaluation of atazanavir C <sub>trough</sub> , atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. <i>New Microbiologica</i> , 2005, 28, 119-25.	0.1	15

#	ARTICLE	IF	CITATIONS
91	World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2022, 124, S1-S3.	3.3	15
92	Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. <i>European Respiratory Journal</i> , 2022, 59, 2200388.	6.7	15
93	Evaluation of the BD MAX <sup>®</sup> , <sup>®</sup> MDR-TB assay in a real-world setting for the diagnosis of pulmonary and extra-pulmonary TB. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1321-1327.	2.9	14
94	WHO drug-resistant TB guidelines 2022: what is new?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 590-591.	1.2	14
95	Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?. <i>International Journal of Infectious Diseases</i> , 2020, 92, S5-S9.	3.3	13
96	Tuberculosis a re-emerging disease. <i>Internal and Emergency Medicine</i> , 2012, 7, 185-187.	2.0	12
97	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. <i>European Respiratory Journal</i> , 2016, 47, 1288-1290.	6.7	12
98	Burden and Characteristics of the Comorbidity Tuberculosis <sup>®</sup> Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy337.	0.9	12
99	Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1222-1224.	5.6	11
100	Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2020, 55, 1901908.	6.7	11
101	Atypical mycobacterial infections <sup>®</sup> management and when to treat. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 216-223.	2.6	11
102	Offer of rapid testing and alternative biological samples as practical tools to implement HIV screening programs. <i>New Microbiologica</i> , 2009, 32, 391-6.	0.1	11
103	Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 480-481.	9.1	10
104	Tuberculosis and its future in the COVID-19 era: The Pulmonology series 2021. <i>Pulmonology</i> , 2021, 27, 94-96.	2.1	10
105	World Tuberculosis Day 2021 Theme <sup>®</sup> <sup>®</sup> “The Clock is Ticking <sup>™</sup> <sup>®</sup> ” and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2021, 113, S1-S6.	3.3	10
106	Armed conflict and human displacement may lead to an increase in the burden of tuberculosis in Europe. <i>International Journal of Infectious Diseases</i> , 2022, 124, S104-S106.	3.3	10
107	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220087.	0.7	10
108	Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 <sup>®</sup> <sup>®</sup> “Wanted: Leaders for a TB-Free World. You can make history. End TB <sup>®</sup> ” <i>International Journal of Infectious Diseases</i> , 2018, 68, 122-124.	3.3	9

#	ARTICLE	IF	CITATIONS
109	History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis. <i>Presse Medicale</i> , 2022, 51, 104112.	1.9	9
110	Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2734.	2.5	8
111	The war in Ukraine and potential consequences for the TB epidemic in Europe. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 470-471.	1.2	8
112	Back pain, leg swelling and a cardiac arrest: an interesting case of endocarditis. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013202215-bcr2013202215.	0.5	7
113	Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study. <i>Respiratory Medicine</i> , 2017, 132, 68-75.	2.9	7
114	Diagnostic pitfalls of urogenital tuberculosis. <i>Tropical Medicine and International Health</i> , 2021, 26, 753-759.	2.3	7
115	Endomysial versus gliadin antibodies in diagnosis of coeliac disease in short children with no gastrointestinal symptoms. <i>Lancet, The</i> , 1991, 338, 521.	13.7	6
116	Shigellosis and toxic megacolon secondary to <i>Shigella flexneri</i> serotype 3a: The challenges of laboratory diagnosis. <i>International Journal of Infectious Diseases</i> , 2018, 70, 104-106.	3.3	6
117	Breast tuberculosis in East London: A 13-year retrospective observational study. <i>Breast Journal</i> , 2020, 26, 235-239.	1.0	6
118	Commemorating World TB Day 2020: "It's TIME" It's time to End the Global TB Epidemic. <i>International Journal of Infectious Diseases</i> , 2020, 92, S1-S4.	3.3	6
119	Post-TB disease: a new topic for investigation and why it matters. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 258-261.	1.2	6
120	Pulmonary tuberculosis in intensive care setting, with a focus on the use of severity scores, a multinational collaborative systematic review. <i>Pulmonology</i> , 2022, 28, 297-309.	2.1	6
121	Clinical standards for drug-susceptible pulmonary TB. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 592-604.	1.2	6
122	Inverse psoriasis. <i>Clinical Medicine</i> , 2015, 15, 311.	1.9	5
123	Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?. <i>European Respiratory Journal</i> , 2016, 48, 1230-1233.	6.7	5
124	The Need for Global Regulation of Antibiotics: The Case of a Generic Oral Penem. <i>Clinical Infectious Diseases</i> , 2016, 62, 1466-1467.	5.8	5
125	Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!. <i>EBioMedicine</i> , 2018, 29, 11-12.	6.1	5
126	Management and outcomes of severe childhood tuberculosis in the pediatric intensive care setting: can we identify best practices?. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20190043.	0.7	5



#	ARTICLE	IF	CITATIONS
127	Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. <i>Antibiotics</i> , 2021, 10, 1355.	3.7	5
128	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: A pilot randomised trial. <i>Journal of Clinical Virology</i> , 2010, 47, 253-257.	3.1	4
129	A strange case of waitress headache. <i>Lancet, The</i> , 2011, 378, 1824.	13.7	4
130	Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. <i>BMJ Open</i> , 2020, 10, e035350.	1.9	4
131	Screening for tuberculosis among high-risk groups attending London emergency departments: a prospective observational study. <i>European Respiratory Journal</i> , 2021, 57, 2003831.	6.7	4
132	New and repurposed drugs. , 0, , 179-204.		4
133	Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?. <i>International Journal of Infectious Diseases</i> , 2017, 65, 133-134.	3.3	3
134	World Tuberculosis Day March 24th 2019 Theme: "TIME" International Journal of Infectious Diseases Tuberculosis Theme Series. <i>International Journal of Infectious Diseases</i> , 2019, 80, S1-S5.	3.3	3
135	The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 358-366.	1.2	3
136	Bronchopleural fistula, tuberculous empyema and bilateral lung destruction treated in various stages by medical and surgical intervention. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 30, 241-243.	0.6	2
137	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1489-1490.	5.6	2
138	Extraspinal articular tuberculosis: An 11-year retrospective study of demographic features and clinical outcomes in East London. <i>Journal of Infection</i> , 2020, 81, 383-389.	3.3	2
139	A case of Clival Tuberculosis and associated meningitis. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2021, 25, 100273.	1.3	2
140	The case for expanding worldwide access to point of care molecular drug susceptibility testing for isoniazid. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1047-1049.	6.0	2
141	Protecting ourselves from tuberculosis. Describing a historic poster printed in Italy on 1937. <i>Lung India</i> , 2014, 31, 425.	0.7	1
142	WHO recommendations for multidrug-resistant tuberculosis "Authors" reply. <i>Lancet, The</i> , 2016, 388, 2234-2235.	13.7	1
143	Post-implementation blues: the unfulfilled potential of Xpert. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 1073-1073.	1.2	1
144	Defining the best regimen to treat isoniazid-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 233-235.	10.7	1

#	ARTICLE	IF	CITATIONS
145	Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702187.	6.7	1
146	A postgraduate qualification in tuberculosisâ€”Message in a bottle. <i>International Journal of Infectious Diseases</i> , 2020, 92, S100-S102.	3.3	1
147	TB management in the European Union/European Economic Area: a multiâ€œentre survey. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 126-133.	1.2	1
148	Multi-drug Resistant Tuberculosis Management. , 2021, , 279-294.		1
149	Investigating the response to COVID-19 and understanding severe TB cases: The 2022 Pulmonology TB series. <i>Pulmonology</i> , 2022, 28, 155-157.	2.1	1
150	Case studies to illustrate good practice in the management of non-tuberculous mycobacterial pulmonary disease. <i>Respiratory Medicine Case Reports</i> , 2022, 38, 101668.	0.4	1
151	Differential diagnosis of a palmar and plantar rash. <i>BMJ, The</i> , 2013, 347, f5542-f5542.	6.0	0
152	Giant thoracic aorta aneurysm causing airway and esophagus stenosis. <i>Monaldi Archives for Chest Disease</i> , 2015, 77, 145-6.	0.6	0
153	P118â€œ...How do foreign-born patients with tuberculosis access healthcare? a cohort analysis of referrals from general practice and the emergency department to a tertiary tuberculosis service. <i>Thorax</i> , 2016, 71, A147.1-A147.	5.6	0
154	Non-tuberculous mycobacterial pulmonary disease: a clinical update. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018, 79, C118-C122.	0.5	0
155	P209â€œ...Chest wall tuberculosis presentations in east london. , 2019, , .		0
156	Regimen design and pharmacokineticâ€œpharmacodynamic science: lessons learned. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 3-4.	9.1	0
157	What is the best regimen to treat latent tuberculosis infection?. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 263-264.	9.1	0
158	Intermittent regimens for tuberculosis treatment: Back to the Future?. <i>European Respiratory Journal</i> , 2020, 56, 2002510.	6.7	0
159	Green Light Committee and drug-resistant-tuberculosis: how to address the new challenges?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 539-539.	1.2	0
160	Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study. <i>BMJ Open</i> , 2021, 11, e052885.	1.9	0
161	P158â€œ...Extra-pulmonary tuberculosis (EPTB): a comparison between UK-born and foreign-born populations in East London. , 2021, , .		0
162	Socio-demographic and clinical characteristics of patients with tuberculosis and diabetes in European countries. A TB-net study. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
163	Breast tuberculosis in East London. , 2016, , .		0
164	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis. , 2016, , .		0
165	Cohort analysis of a large community-based latent tuberculosis screening and treatment programme in a high incidence setting in East London. , 2016, , .		0
166	A retrospective case series: Bone and joint TB in North East London. , 2016, , .		0
167	Oesophageal perforation secondary to tuberculous lymphadenitis: Experience of a tertiary centre. , 2016, , .		0
168	Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis. , 2016, , .		0
169	Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results. , 2017, , .		0
170	Retrospective Cohort Study over a period of 5 years of Spinal Tuberculosis at a large London Tertiary Centre. , 2017, , .		0
171	Tb or not Tb; that is the paradoxical reaction. , 2017, , .		0
172	Five year Cohort Analysis of Non-Tuberculosis Mycobacterium Lung Disease at a Tertiary Referral Centre. , 2017, , .		0
173	Clinical cases. , 0, , 446-460.		0